Off-label prescription: experience is a gloomy lantern that does not even illuminate its bearer. Author response
We fully agree with Alain Braillon [1] that the question of whether to promote or restrict therapeutic off-label drug use is multifaceted. In our study [2], we explored the clinical trial evidence as only one of the many facets. Our findings suggest a mixed picture regarding the comparative effectiveness of off-label uses, which requires a careful consideration of the clinical evidence on a case-by-case basis. We believe that this finding should inform policy decisions on off-label drug use, but many other aspects remain clearly important and should receive equal consideration.
Source: Journal of Clinical Epidemiology - Category: Epidemiology Authors: Aviv Ladanie, John P.A. Ioannidis, Randall S. Stafford, Hannah Ewald, Heiner C. Bucher, Lars G. Hemkens, Lars G. Hemkens Tags: Letter to the Editor Source Type: research